Combination treatment for high blood pressure in obesity
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether combining two medications, finerenone and empagliflozin, can lower blood pressure in people with obesity and high blood pressure. It may offer a new option for managing both conditions together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older.
- You have a body mass index (BMI) of 28 or higher, or you have extra weight around your belly (waist circumference or waist-to-hip ratio above certain levels).
- Your systolic blood pressure (the top number) is between 140 and 159 mmHg when measured in the clinic.
- You are currently taking no more than two blood pressure medications, and your dose has not changed in the last 4 weeks.
- You do not have diabetes, heart failure, or severe kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
This study tests whether taking two medications together—finerenone and semaglutide—can help protect kidney function in people with obesity and chronic kidney disease who have protein in their urine. The goal is to see if this combination is safe and effective for slowing kidney damage.
This study tests a diabetes medication called empagliflozin to see if it helps improve the health of blood vessels in people with slightly elevated blood pressure. It may help protect blood vessels from damage that can lead to heart problems later.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
Hear when a new Hypertension (HTN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.